Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability, and pharmacokinetics of olanzapine and samidorphan in
clinically stable pediatric subjects (10 to 12 years old) with Bipolar I disorder following
oral administration of multiple ascending doses of OLZ/SAM